The company’s investment into the outfitting of a new facility comes not much more than a year after launch and will include two manufacturing lines, as well as technical areas, offices and laboratories.
ten23 health’s immediate plan is to complete the superstructure of the facility, which is expected be finished during summer 2022. Following this, the contract development and manufacturing organization (CDMO) will add two sterile manufacturing lines to the company’s existing filling line.
The first of these additions will provide fill and finish capacity for commercial and clinical use. The line will be designed to handle ready-to-use containers, which includes syringes, cartridges, and special primary packaging, such as administrative devices for subcutaneous delivery.
The CDMO plans for the line to be operational by 2024 and it will possess a total annual capacity of 20 million units.
An additional line is also due to be added to the facility, with the second line set to offer the ability to fill bulk containers (vials), both in liquid and lyophilized form, with two larger-scale freeze-driers, for both clinical and commercial use. The annual total capacity for this is line expected to be 12.5 million units.
As well as boosting its overall production capacity, ten23 expects the new facility to add more than 100 jobs in the Visp, Switzerland region.
The new CDMO had moved rapidly to expand its services, backed by 3i Group. The latter organization is a multinational private equity and venture capacity company based in London, UK.
According to 3i, at the launch of ten23, the CDMO will be supported with between €100 to €500m ($522m) in capital. BioPharma-Reporter reached out to ten23 to learn of the size of investment used for this latest expansion but a spokesperson declined to give specifics on the capital utilized.
The expansion to its Visp location actually marks the second expansion in the last few months, with the CDMO previously announcing that it would add 1,000-square-meters of clean-room space.
At the time, ten23 stated that the move would allow for additional services to be carried out, such as supporting device assembly operations, labeling and secondary packaging.
CEO of ten23, Hanns-Christian Mahler, stated that the most recent expansion was “a clear commitment for Switzerland.”
Its expansion in the Visp area adds to an already significant manufacturing, given it also houses a significant proportion of Lonza’s production capabilities. Broadly, Switzerland is undergoing rapid development not just in manufacturing but with a booming biotech industry, as it recently reported record investment flowing into the space and increasing number of employees working in the space.